Recent interest in Insulet (PODD) is being driven by fresh clinical data on its investigational Omnipod 6 system and fully closed-loop technology for type 2 diabetes, along with newly rolled out U.S. upgrades to Omnipod 5.

Despite the latest Omnipod 6 and Omnipod 5 headlines, Insulet’s share price has been under pressure, with the 90 day share price return down 35.9% and the 1 year total shareholder return down 51.5%. This signals weak momentum even as product news builds.

If you are tracking how diabetes technology is evolving, it can help to widen your watchlist to other healthcare AI opportunities through the 40 healthcare AI stocks.

So with Insulet’s stock down sharply over the past year despite positive Omnipod data and an indicated intrinsic discount of about 56%, are you looking at a genuine value opportunity, or a market that already reflects future growth?

Most Popular Narrative: 38.1% Undervalued

Based on the most followed narrative, Insulet’s fair value of $238.69 sits well above the last close at $147.69, setting up a wide valuation gap that hinges on how its diabetes automation roll out actually plays out.

Management plans to spend about US$1b on R&D over three years, expand manufacturing in Malaysia and build a new plant in Costa Rica that is expected to be operational in 2029, and is also ramping AI and data platforms, so any execution issues in scaling production, integrating new algorithms such as Omnipod 6 or the fully closed loop type 2 system, or delays in studies like STRIVE and EVOLUTION could raise costs, dampen gross margin expansion and slow adjusted EPS growth.

This narrative leans heavily on stronger earnings, wider margins and a future profit multiple that assumes Omnipod’s growth plan stays on track. Want to see how those revenue targets, margin steps and valuation all connect to that $238.69 figure? The full narrative lays out the specific assumptions and timing that need to line up for Insulet’s stock to close this gap.

Result: Fair Value of $238.69 (UNDERVALUED)

However, this Insulet thesis could be challenged if automated insulin delivery uptake slows in key diabetes segments, or if execution issues at new manufacturing sites pressure margins and earnings.

Next Steps

Given the mix of optimism and concern around Insulet right now, it makes sense to move quickly and test the numbers against your own expectations by weighing the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Insulet?

If Insulet has your attention, do not stop there, use the Simply Wall Street Screener to spot other opportunities that could fit your style and risk comfort.

• Target resilient balance sheets by filtering for companies on the solid balance sheet and fundamentals stocks screener (48 results) to see which businesses pair financial strength with fundamental support.
• Hunt for potential mispricings with the 44 high quality undervalued stocks and compare stocks whose fundamentals may not line up with their current market prices.
• Spot early-stage opportunities using the 23 elite penny stocks with strong financials before wider attention arrives, so you can assess whether any fit your return and risk expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.